Patents by Inventor Ing-Ming Chiu
Ing-Ming Chiu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190351022Abstract: The present application provides a composition and methods to enhance nerve regeneration utilizing at least one component of neural stem cells or IL12p40. The composition comprises neural stem cells and a neurotrophic factor, which is constructed by IL12p40 as at least one subunit. The methods to enhance nerve regeneration comprise providing a nerve regeneration composition comprising a neurotrophic factor containing IL12p40 as at least one subunit to a subject. The composition of the methods can further comprise neural stem cells.Type: ApplicationFiled: July 17, 2019Publication date: November 21, 2019Applicant: National Health Research InstitutesInventors: Ing-Ming CHIU, Ya-Hui CHI, Don-Ching LEE
-
Patent number: 10391149Abstract: The present application provides a composition and methods to enhance nerve regeneration utilizing at least one component of neural stem cells or IL12p40. The composition comprises neural stem cells and a neurotrophic factor, which is constructed by IL12p40 as at least one subunit. The methods to enhance nerve regeneration comprise providing a nerve regeneration composition comprising a neurotrophic factor containing IL12p40 as at least one subunit to a subject. The composition of the methods can further comprise neural stem cells.Type: GrantFiled: August 14, 2015Date of Patent: August 27, 2019Assignee: NATIONAL HEALTH RESEARCH INSTITUTESInventors: Ing-Ming Chiu, Ya-Hui Chi, Don-Ching Lee
-
Patent number: 10000732Abstract: A microfluidic dual-well device is disclosed. The device comprises: (a) a first substrate having a first end, a second end, and a culture microwell forming portion; (b) a plurality of culture microwells; (c) a second substrate having a first end, a second end, and a capture microwell forming portion, the two ends of the second substrate being respectively bounded to the two ends of the first substrate; (d) a plurality of capture microwells; (e) a microfluidic channel; (f) a microfluidic inlet port; and (g) a microfluidic outlet port; wherein the microfluidic channel is in fluidic connections with the culture microwells, the capture microwells, and the inlet and outlet ports. Methods of capturing and transferring a single cell or a single cell colony for culture, and method of transferring a target cell from a polydimethylsiloxane (PDMS) structure of culture microwells to a culture plate for culture are also disclosed.Type: GrantFiled: May 19, 2016Date of Patent: June 19, 2018Assignee: NATIONAL HEALTH RESEARCH INSTITUTESInventors: Chia-Hsien Hsu, Ching-Hui Lin, Hao-Chen Chang, Ing-Ming Chiu
-
Publication number: 20170224776Abstract: The present application provides a composition and methods to enhance nerve regeneration utilizing at least one component of neural stem cells or IL12p40. The composition comprises neural stem cells and a neurotrophic factor, which is constructed by IL12p40 as at least one subunit. The methods to enhance nerve regeneration comprise providing a nerve regeneration composition comprising a neurotrophic factor containing IL12p40 as at least one subunit to a subject. The composition of the methods can further comprise neural stem cells.Type: ApplicationFiled: August 14, 2015Publication date: August 10, 2017Applicant: National Health Research InstitutesInventors: Ing-Ming CHIU, Ya-Hui CHI, Don-Ching LEE
-
Publication number: 20170145363Abstract: A microfluidic dual-well device is disclosed. The device comprises: (a) a first substrate having a first end, a second end, and a culture microwell forming portion; (b) a plurality of culture microwells; (c) a second substrate having a first end, a second end, and a capture microwell forming portion, the two ends of the second substrate being respectively bounded to the two ends of the first substrate; (d) a plurality of capture microwells; (e) a microfluidic channel; (f) a microfluidic inlet port; and (g) a microfluidic outlet port; wherein the microfluidic channel is in fluidic connections with the culture microwells, the capture microwells, and the inlet and outlet ports. Methods of capturing and transferring a single cell or a single cell colony for culture, and method of transferring a target cell from a polydimethylsiloxane (PDMS) structure of culture microwells to a culture plate for culture are also disclosed.Type: ApplicationFiled: May 19, 2016Publication date: May 25, 2017Inventors: Chia-Hsien HSU, Ching-Hui LIN, Duane S. JUANG, Hao-Chen CHANG, Ing-Ming CHIU
-
Patent number: 8496956Abstract: Implantable nerve regeneration conduits and methods of making the same are disclosed. The implantable nerve regeneration conduits mainly comprise a biodegradable polymer and a metal. Moreover, the conduits may also comprise one or more nerve regeneration enhancing elements, which comprise bioactive molecules or cells. The inner surface of the conduits may be micropatterned photolithographic processes to form microgrooves for facilitating cell alignment.Type: GrantFiled: June 25, 2009Date of Patent: July 30, 2013Assignee: National Health Research InstitutesInventors: Ing-Ming Chiu, Shan-hui Hsu
-
Patent number: 8357832Abstract: A trifusion reporter plasmid is described that comprises a plasmid operably coupled to a mammalian FGF1B promoter that is operably coupled to a bioluminescence gene fused to a fluorescence gene fused to a nuclear medical imaging gene. The new reporter allows in vivo or ex vivo detection of gene expression in three different ways, in addition to traditional in vitro detection methods. Transgenic animals containing this new trifusion reporter and uses of same are described.Type: GrantFiled: January 26, 2012Date of Patent: January 22, 2013Assignee: National Health Research InstitutesInventors: Kurt M. Lin, Ing-Ming Chiu
-
Publication number: 20120144507Abstract: A trifusion reporter plasmid is described that comprises a plasmid operably coupled to a mammalian FGF1B promoter that is operably coupled to a bioluminescence gene fused to a fluorescence gene fused to a nuclear medical imaging gene. The new reporter allows in vivo or ex vivo detection of gene expression in three different ways, in addition to traditional in vitro detection methods. Transgenic animals containing this new trifusion reporter and uses of same are described.Type: ApplicationFiled: January 26, 2012Publication date: June 7, 2012Applicant: National Health Research InstitutesInventors: Kurt M. Lin, Ing-Ming Chiu
-
Patent number: 8129181Abstract: A trifusion reporter plasmid is described that comprises a plasmid operably coupled to a mammalian FGF1B promoter that is operably coupled to a bioluminescence gene fused to a fluorescence gene fused to a nuclear medical imaging gene. The new reporter allows in vivo or ex vivo detection of gene expression in three different ways, in addition to traditional in vitro detection methods. Transgenic animals containing this new trifusion reporter and uses of same are described.Type: GrantFiled: July 24, 2009Date of Patent: March 6, 2012Assignee: National Health Research InstitutesInventors: Kurt M. Lin, Ing-Ming Chiu
-
Patent number: 8101409Abstract: Compositions for promoting growth and/or differentiation of a stem cell are disclosed. The composition comprises: a) a diamond film; b) a stem cell cultured on the diamond film; and c) a medium bathing the stem cell. The stem cell may be a mammalian neural stem cell and the diamond film may comprise a hydrogen-terminated or an oxygen-terminated surface. The hydrogen-terminated surface promotes proliferation and differentiation of a neural stem cell into neurons, and the oxygen-terminated surface promotes a neural stem cell to proliferate and differentiate into oligodendrocytes.Type: GrantFiled: October 5, 2009Date of Patent: January 24, 2012Assignees: National Health Research Institutes, National Tsing Hua UniversityInventors: Ing-Ming Chiu, Ying-Chieh Chen, Don-Ching Lee, Nyan-Hwa Tai
-
Publication number: 20110081395Abstract: Compositions for promoting growth and/or differentiation of a stem cell are disclosed. The composition comprises: a) a diamond film; b) a stem cell cultured on the diamond film; and c) a medium bathing the stem cell. The stem cell may be a mammalian neural stem cell and the diamond film may comprise a hydrogen-terminated or an oxygen-terminated surface. The hydrogen-terminated surface promotes proliferation and differentiation of a neural stem cell into neurons, and the oxygen-terminated surface promotes a neural stem cell to proliferate and differentiate into oligodendrocytes.Type: ApplicationFiled: October 5, 2009Publication date: April 7, 2011Applicants: NATIONAL HEALTH RESEARCH INSTITUTES, NATIONAL TSING HUA UNIVERSITYInventors: ING-MING CHIU, YING-CHIEH CHEN, DON-CHING LEE, NYAN-HWA TAI
-
Publication number: 20110023136Abstract: A trifusion reporter plasmid is described that comprises a plasmid operably coupled to a mammalian FGF1B promoter that is operably coupled to a bioluminescence gene fused to a fluorescence gene fused to a nuclear medical imaging gene. The new reporter allows in vivo or ex vivo detection of gene expression in three different ways, in addition to traditional in vitro detection methods. Transgenic animals containing this new trifusion reporter and uses of same are described.Type: ApplicationFiled: July 24, 2009Publication date: January 27, 2011Applicant: National Health Research InstitutesInventors: Kurt M. Lin, Ing-Ming Chiu
-
Patent number: 7745214Abstract: A transgenic, non-human mammal useful for assessing the effect of candidate chemotherapeutic drugs on the growth of brain tumors in vivo is provided. Incorporated into the genome of the transgenic mammal, which preferably is a rodent, is a transgene which comprises a promoter comprising the nuclear factor binding region of the RR2 cis acting element of a fibroblast growth factor 1B (FGF1B) promoter. Operably linked to the promoter is reporter gene comprising a sequence which encodes the SV40 large T antigen. A transgenic, non-human mammal useful for identifying and isolating FGF1 producing brain cells. Incorporated into the genome of these transgenic animals is a transgene which comprises a promoter comprising the nuclear factor binding region of the RR2 cis acting element of an fibroblast growth factor 1B (FGF1B) promoter. Operably linked to the promoter is reporter gene comprising a sequence which encodes a protein or polypeptide other than an SV40 large T antigen.Type: GrantFiled: March 15, 2006Date of Patent: June 29, 2010Inventor: Ing-Ming Chiu
-
Publication number: 20100068240Abstract: Implantable nerve regeneration conduits and methods of making the same are disclosed. The implantable nerve regeneration conduits mainly comprise a biodegradable polymer and a metal. Moreover, the conduits may also comprise one or more nerve regeneration enhancing elements, which comprise bioactive molecules or cells. The inner surface of the conduits may be micropatterned photolithographic processes to form microgrooves for facilitating cell alignment.Type: ApplicationFiled: June 25, 2009Publication date: March 18, 2010Applicant: NATIONAL HEALTH RESEARCH INSTITUTESInventors: Ing-Ming Chiu, Shan-hui Hsu
-
Publication number: 20070061908Abstract: A transgenic, non-human mammal useful for assessing the effect of candidate chemotherapeutic drugs on the growth of brain tumors in vivo is provided. Incorporated into the genome of the transgenic mammal, which preferably is a rodent, is a transgene which comprises a promoter comprising the nuclear factor binding region of the RR2 cis acting element of a fibroblast growth factor 1B (FGF1B) promoter. Operably linked to the promoter is reporter gene comprising a sequence which encodes the SV40 large T antigen. A transgenic, non-human mammal useful for identifying and isolating FGF1 producing brain cells. Incorporated into the genome of these transgenic animals is a transgene which comprises a promoter comprising the nuclear factor binding region of the RR2 cis acting element of an fibroblast growth factor 1B (FGF1B) promoter. Operably linked to the promoter is reporter gene comprising a sequence which encodes a protein or polypeptide other than an SV40 large T antigen.Type: ApplicationFiled: March 15, 2006Publication date: March 15, 2007Inventor: Ing-Ming Chiu
-
Publication number: 20060217310Abstract: Provided are compositions comprising a fibroblast growth factor 1 (FGF-1) for skin care, and methods of use of such compositions. The FGF-1 is constructed into a recombinant expression vector, and characterized by the molecular characteristics. The FGF-1 can modulate mitogenic activities and mediate both the FGF-2 and KGF signaling pathway that can promote proliferation of fibroblast cells and epidermal cells. A mutant FGF-1 has the longer half life than wild type has in virtue of its capabilities of anti-oxidization or no further proteolytic degradation.Type: ApplicationFiled: March 23, 2006Publication date: September 28, 2006Inventors: Ing-Ming Chiu, Toko Wen
-
Patent number: 7045678Abstract: A transgenic, non-human mammal useful for assessing the effect of candidate chemotherapeutic drugs on the growth of brain tumors in vivo is provided. Incorporated into the genome of the transgenic mammal, which preferably is a rodent, is a transgene which comprises a promoter comprising the nuclear factor binding region of the RR2 cis acting element of a fibroblast growth factor 1B (FGF1B) promoter. Operably linked to the promoter is reporter gene comprising a sequence which encodes the SV40 large T antigen. A transgenic, non-human mammal useful for identifying and isolating FGF1 producing brain cells. Incorporated into the genome of these transgenic animals is a transgene which comprises a promoter comprising the nuclear factor binding region of the RR2 cis acting element of an fibroblast growth factor 1B (FGF1B) promoter. Operably linked to the promoter is reporter gene comprising a sequence which encodes a protein or polypeptide other than an SV40 large T antigen.Type: GrantFiled: April 22, 2004Date of Patent: May 16, 2006Inventor: Ing-Ming Chiu
-
Patent number: 6984518Abstract: A transgenic, non-human mammal useful for assessing the effect of candidate chemotherapeutic drugs on the growth of brain tumors in vivo is provided. Incorporated into the genome of the transgenic mammal, which preferably is a rodent, is a transgene which comprises a promoter comprising the nuclear factor binding region of the RR2 cis acting element of a fibroblast growth factor 1B (FGF1B) promoter. Operably linked to the promoter is reporter gene comprising a sequence which encodes the SV40 large T antigen. A transgenic, non-human mammal useful for identifying and isolating FGF1 producing brain cells. Incorporated into the genome of these transgenic animals is a transgene which comprises a promoter comprising the nuclear factor binding region of the RR2 cis acting element of an fibroblast growth factor 1B (FGF1B) promoter. Operably linked to the promoter is reporter gene comprising a sequence which encodes a protein or polypeptide other than an SV40 large T antigen.Type: GrantFiled: November 21, 2001Date of Patent: January 10, 2006Inventor: Ing-Ming Chiu
-
Publication number: 20040187172Abstract: A transgenic, non-human mammal useful for assessing the effect of candidate chemotherapeutic drugs on the growth of brain tumors in vivo is provided. Incorporated into the genome of the transgenic mammal, which preferably is a rodent, is a transgene which comprises a promoter comprising the nuclear factor binding region of the RR2 cis acting element of a fibroblast growth factor 1B (FGF1B) promoter. Operably linked to the promoter is reporter gene comprising a sequence which encodes the SV40 large T antigen. A transgenic, non-human mammal useful for identifying and isolating FGF1 producing brain cells. Incorporated into the genome of these transgenic animals is a transgene which comprises a promoter comprising the nuclear factor binding region of the RR2 cis acting element of an fibroblast growth factor 1B (FGF1B) promoter. Operably linked to the promoter is reporter gene comprising a sequence which encodes a protein or polypeptide other than an SV40 large T antigen.Type: ApplicationFiled: April 22, 2004Publication date: September 23, 2004Inventor: Ing-Ming Chiu
-
Publication number: 20020104114Abstract: A transgenic, non-human mammal useful for assessing the effect of candidate chemotherapeutic drugs on the growth of brain tumors in vivo is provided. Incorporated into the genome of the transgenic mammal, which preferably is a rodent, is a transgene which comprises a promoter comprising the nuclear factor binding region of the RR2 cis acting element of a fibroblast growth factor 1B (FGF1B) promoter. Operably linked to the promoter is reporter gene comprising a sequence which encodes the SV40 large T antigen. A transgenic, non-human mammal useful for identifying and isolating FGF1 producing brain cells. Incorporated into the genome of these transgenic animals is a transgene which comprises a promoter comprising the nuclear factor binding region of the RR2 cis acting element of an fibroblast growth factor 1B (FGF1B) promoter. Operably linked to the promoter is reporter gene comprising a sequence which encodes a protein or polypeptide other than an SV40 large T antigen.Type: ApplicationFiled: November 21, 2001Publication date: August 1, 2002Inventor: Ing-Ming Chiu